BI 660848

Drug Profile

BI 660848

Latest Information Update: 28 Feb 2011

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Analgesics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Suspended Neuropathic pain

Most Recent Events

  • 14 Feb 2011 Boehringer Ingelheim terminates phase I trial in Neuropathic pain in Germany (NCT01145014)
  • 05 Nov 2010 Suspended - Phase-I for Neuropathic pain in Germany (PO, liquid)
  • 05 Nov 2010 Suspended - Phase-I for Neuropathic pain in Germany (PO, immediate release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top